Improvements in Patient-Reported Outcomes After Treatment With Deucravacitinib in Patients With Psoriatic Arthritis: Results From a Randomized Phase 2 Trial.
Vibeke StrandLaure GossecLaura C CoatesAlexis OgdieJiyoon ChoiBrandon BeckerJoe ZhuoThomas LehmanMiroslawa NowakAyanbola ElegbePhillip J MeaseAtul A DeodharPublished in: Arthritis care & research (2024)
Deucravacitinib groups demonstrate significant and clinically meaningful improvements in PROs versus placebo in patients with active PsA, which warrants further study.